HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Genmab (NASDAQ:GMAB) and maintained a price target of $50, indicating confidence in the company's future performance.
September 20, 2024 | 10:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Genmab, maintaining a $50 price target. This suggests continued confidence in Genmab's performance and potential for stock appreciation.
The reiteration of a Buy rating and maintenance of a $50 price target by HC Wainwright & Co. indicates strong confidence in Genmab's future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100